Behind Third Rock

August 28, 2013 | Third Rock Ventures invests heavily in biotech, now taking on projects for "ultra-orphan" diseases. Though the risks are high, the rewards are too. A recent acquisition could could net Third Rock a 20-fold payout for their investment. But that's just the money. The real winners might be the patients for whom the research is targeted. Boston Magazine